Drugs / VGCV
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06102525 Background | Oct 2024 → Mar 2029 expected | glioblastoma | Rznomics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGCV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06102525 ↗ |
| Modality | Small molecule | “is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases” NCT06102525 ↗ |
| Route | Oral | “An approved oral VGCV will be used in the proposed clinical study of RZ-001.” NCT06102525 ↗ |